LOS ANGELES, CA–(Marketwired – Nov 11, 2013) – Fresh Start Private Management, Inc. (OTCQB: CEYY), a leader in alcohol treatment and rehabilitation programs executed a letter of intent earlier this year to sell the exclusive license and distribution rights of its treatment program consisting of a proprietary Naltrexone implant formula and coaching program to an investor for the entire country of Mexico. Under the terms of the pending agreement, Fresh Start Private would receive an upfront licensing fee and running royalties on sales in the entire country. With the due diligence phase nearly complete, both sides are resuming discussions to complete the agreement.
The population of Mexico is over 112 million people and the country has an enormous alcohol abuse problem. This pending agreement creates the potential to help countless families suffering from alcoholism there and would create an entirely new revenue stream for Fresh Start Private.
Fresh Start Private will provide further information regarding these discussions upon reaching a definitive agreement.
“We are very confident that we can get this deal completed now that months have been spent on due diligence about our program and the viability of it in Mexico. This investor has vast marketing power in Mexico which will allow them to bring immediate and substantial awareness to the Fresh Start Private program there,” said Kent Emry, CEO of Fresh Start Private. “This deal could represent millions of dollars annually in royalties without much overhead. That could increase exponentially if we take that model to other countries.”
About Fresh Start Private
Fresh Start Private Management, Inc. (OTCQB: CEYY) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a highly effective program consisting of two main components used by various alcohol addiction clinics in the US. Clinic reports show that the treatment program has an 85% success rate with individuals that complete the program. The first component of the program consists of an outpatient implant procedure performed by a licensed physician that delivers targeted, therapeutic levels of the drug Naltrexone, an opiate antagonist that significantly reduces physical cravings for alcohol, into the body. The second component of the program developed by Fresh Start Private is a one on one coaching program specifically tailored for the treatment of alcoholism. For more information on CEYY, please visit www.freshstartprivate.com
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
Investor Relations Contact:
Maximum Performance Advisors, Inc.